OCX OncoCyte Corp

Price (delayed)

$2.51

Market cap

$20.77M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.75

Enterprise value

$12.5M

Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum. The Company, through its proprietary tests and pharmaceutical ...

Highlights
The company's EPS has surged by 72% YoY and by 61% QoQ
OncoCyte's net income has surged by 62% YoY and by 52% QoQ
OncoCyte's equity has decreased by 46% QoQ and by 40% YoY
OCX's quick ratio is down by 27% since the previous quarter and by 19% year-on-year

Key stats

What are the main financial stats of OCX
Market
Shares outstanding
8.27M
Market cap
$20.77M
Enterprise value
$12.5M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.01
Price to sales (P/S)
12.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.32
Earnings
Revenue
$1.5M
EBIT
-$27.73M
EBITDA
-$26.05M
Free cash flow
-$23.25M
Per share
EPS
-$3.75
Free cash flow per share
-$3.04
Book value per share
$2.48
Revenue per share
$0.2
TBVPS
$2.39
Balance sheet
Total assets
$74.89M
Total liabilities
$49.3M
Debt
$2.87M
Equity
$20.47M
Working capital
$3.5M
Liquidity
Debt to equity
0.14
Current ratio
1.49
Quick ratio
1.61
Net debt/EBITDA
0.32
Margins
EBITDA margin
-1,733.1%
Gross margin
27.5%
Net margin
-1,848.4%
Operating margin
-1,672.4%
Efficiency
Return on assets
-35.2%
Return on equity
-82.3%
Return on invested capital
-523.2%
Return on capital employed
-41%
Return on sales
-1,844.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

OCX stock price

How has the OncoCyte stock price performed over time
Intraday
0.4%
1 week
-0.79%
1 month
-17.97%
1 year
-53.52%
YTD
0.4%
QTD
-14.33%

Financial performance

How have OncoCyte's revenue and profit performed over time
Revenue
$1.5M
Gross profit
$413,000
Operating income
-$25.14M
Net income
-$27.78M
Gross margin
27.5%
Net margin
-1,848.4%
OCX's net margin has surged by 76% year-on-year and by 53% since the previous quarter
OncoCyte's net income has surged by 62% YoY and by 52% QoQ
The revenue has soared by 57% YoY and by 2.7% QoQ
The operating income has declined by 40% year-on-year and by 22% since the previous quarter

Growth

What is OncoCyte's growth rate over time

Valuation

What is OncoCyte stock price valuation
P/E
N/A
P/B
1.01
P/S
12.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.32
The company's EPS has surged by 72% YoY and by 61% QoQ
The stock's price to book (P/B) is 63% less than its 5-year quarterly average of 2.7 but 12% more than its last 4 quarters average of 0.9
OncoCyte's equity has decreased by 46% QoQ and by 40% YoY
The revenue has soared by 57% YoY and by 2.7% QoQ
The price to sales (P/S) is 55% less than the last 4 quarters average of 28.1

Efficiency

How efficient is OncoCyte business performance
The company's return on sales has surged by 76% YoY and by 53% QoQ
OCX's ROIC is up by 48% year-on-year and by 40% since the previous quarter
OCX's return on assets is up by 47% since the previous quarter and by 31% year-on-year
The company's return on equity rose by 46% QoQ and by 30% YoY

Dividends

What is OCX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for OCX.

Financial health

How did OncoCyte financials performed over time
OCX's total assets is 52% greater than its total liabilities
The current ratio has contracted by 29% from the previous quarter and by 29% YoY
OCX's quick ratio is down by 27% since the previous quarter and by 19% year-on-year
OCX's debt is 86% smaller than its equity
The debt to equity has surged by 75% since the previous quarter and by 40% year-on-year
OncoCyte's equity has decreased by 46% QoQ and by 40% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.